Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 11,372 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Recruiting No phase listed Observational

Study of Oral Food Challenge Biomarkers (SAFER)

NCT07279467
View directory record Official record
Conditions
Allergy
Interventions
Oral Food Challenge (OFC): Peanut Protein
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Terminated Phase 2 Interventional Results available

Drosophila-generated CTL

NCT01271907
View directory record Official record
Conditions
Metastatic Cutaneous Melanoma
Interventions
fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 2:24 AM EDT
Recruiting No phase listed Observational

World Trade Center Particulate Matter Induced Cardiorespiratory and Vascular Dysfunction: a MultiOmic Approach (CaRVD)

NCT05215171
View directory record Official record
Conditions
Cardiorespiratory and Vascular Dysfunction, Obstructive Airway Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

NCT07805044
View directory record Official record
Conditions
PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions
Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
Procedure · Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Safety Study of Nifurtimox for Relapsed or Refractory Neuroblastoma

NCT00486564
View directory record Official record
Conditions
Neuroblastoma
Interventions
Nifurtimox
Drug
Lead sponsor
University of Vermont
Other
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
St Louis, Missouri • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 23, 2009 · Synced Oct 30, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

NCT00040664
View directory record Official record
Conditions
HIV Infection
Interventions
ritonavir, fosamprenavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational

Hepatitis B Research Network Pediatric Cohort Study (HBRN)

NCT01263600
View directory record Official record
Conditions
Hepatitis B
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 17 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational

Rescue FMT with Bezlotoxumab for Recurrent C. Difficile Infection

NCT06669936
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
Fecal microbiota transplantation ± bezlotoxumab
Drug
Lead sponsor
Alexander Khoruts
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 30, 2026, 2:24 AM EDT
Not yet recruiting Phase 2 Interventional

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

NCT07634536
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
Interventions
VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide, Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT), Mycophenolate mofetil (MMF), Tacrolimus
Radiation · Drug · Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Active, not recruiting No phase listed Observational

Precision PCI Registry

NCT06143709
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
DNA sample collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

NCT06680232
View directory record Official record
Conditions
HEPATITIS B CHRONIC
Interventions
PBGENE-HBV
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Recruiting No phase listed Observational

Generic Database of Very Low Birth Weight Infants

NCT00063063
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
No Intervention
Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 14 Days
Enrollment
80,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2030
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational

A Study of Ustekinumab Treatment in Children With Crohn's Disease

NCT05242458
View directory record Official record
Conditions
Crohn's Disease
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 25 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 30, 2026, 2:24 AM EDT
Recruiting Phase 3 Interventional

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

NCT06745908
View directory record Official record
Conditions
NSCLC Stage IV
Interventions
N-803, Tislelizumab, Docetaxel, Prior failed checkpoint inhibitor
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Springdale, Arkansas • El Segundo, California • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

NCT06734117
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Elecsys® Troponin T hs Gen 6, Blood sample collection
Diagnostic Test · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years and older
Enrollment
5,429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
El Centro, California • La Jolla, California • Gainesville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 30, 2026, 2:24 AM EDT
Not listed Phase 1 Interventional

Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

NCT05275504
View directory record Official record
Conditions
B-Cell Malignancies
Interventions
TT-01488
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Canton, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

NCT04097704
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 30, 2026, 2:24 AM EDT
Completed Phase 1 Interventional

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00087204
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
becatecarin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 30, 2026, 2:24 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

NCT02401347
View directory record Official record
Conditions
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
Interventions
Talazoparib Tosylate
Drug
Lead sponsor
Melinda Telli
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational

ADPKD Cohort Study

NCT02084849
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Up to 60 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 30, 2026, 2:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single-incision Sling vs Urethral Bulking During Prolapse Surgery for Occult Stress Incontinence

NCT05210738
View directory record Official record
Conditions
Stress Incontinence, Female
Interventions
Single incision sling, Bulkamid bulking agent
Device · Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 30, 2026, 2:24 AM EDT
Recruiting No phase listed Observational

A National Registry For Pulmonary Alveolar Proteinosis

NCT02461615
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 30, 2026, 2:24 AM EDT
Completed Early Phase 1 Interventional

Searching for Persistence of Infection in Lyme Disease

NCT01143558
View directory record Official record
Conditions
Lyme Disease
Interventions
Lyme Disease Xenodiagnosis
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • Bethesda, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 2:24 AM EDT